Michael Roost Clausen

2.4k total citations · 1 hit paper
79 papers, 834 citations indexed

About

Michael Roost Clausen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Michael Roost Clausen has authored 79 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 40 papers in Oncology and 29 papers in Genetics. Recurrent topics in Michael Roost Clausen's work include Lymphoma Diagnosis and Treatment (61 papers), Chronic Lymphocytic Leukemia Research (28 papers) and CAR-T cell therapy research (27 papers). Michael Roost Clausen is often cited by papers focused on Lymphoma Diagnosis and Treatment (61 papers), Chronic Lymphocytic Leukemia Research (28 papers) and CAR-T cell therapy research (27 papers). Michael Roost Clausen collaborates with scholars based in Denmark, United States and United Kingdom. Michael Roost Clausen's co-authors include Kim Linton, Martin Hutchings, Francesco d’Amore, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Dena DeMarco, Tarec Christoffer El‐Galaly, Peter Johnson, Brian Elliott and Rogier Mous and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Roost Clausen

68 papers receiving 826 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Roost Clausen Denmark	14	589	536	163	147	126	79	834
Chaitra S. Ujjani United States	15	487 0.8×	622 1.2×	234 1.4×	53 0.4×	156 1.2×	92	855
Paul J. Bröckelmann Germany	18	637 1.1×	507 0.9×	122 0.7×	70 0.5×	159 1.3×	84	925
Deepa Jagadeesh United States	17	660 1.1×	652 1.2×	273 1.7×	33 0.2×	170 1.3×	123	1.1k
Christina Nickenig Germany	11	378 0.6×	272 0.5×	200 1.2×	50 0.3×	73 0.6×	20	569
Ronit Gurion Israel	17	344 0.6×	381 0.7×	216 1.3×	32 0.2×	102 0.8×	83	830
Reyes Arranz Spain	14	513 0.9×	373 0.7×	133 0.8×	45 0.3×	238 1.9×	36	757
Sergio Cleto Mexico	15	477 0.8×	359 0.7×	91 0.6×	62 0.4×	82 0.7×	36	738
Henry Januszewicz Australia	15	356 0.6×	191 0.4×	102 0.6×	128 0.9×	108 0.9×	23	644
Sumana Devata United States	15	279 0.5×	347 0.6×	86 0.5×	72 0.5×	267 2.1×	52	778
Bertrand Souleau France	9	659 1.1×	355 0.7×	453 2.8×	95 0.6×	105 0.8×	28	866

Countries citing papers authored by Michael Roost Clausen

Since Specialization

Citations

This map shows the geographic impact of Michael Roost Clausen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Roost Clausen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Roost Clausen more than expected).

Fields of papers citing papers by Michael Roost Clausen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Roost Clausen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Roost Clausen. The network helps show where Michael Roost Clausen may publish in the future.

Co-authorship network of co-authors of Michael Roost Clausen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Roost Clausen. A scholar is included among the top collaborators of Michael Roost Clausen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Roost Clausen. Michael Roost Clausen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jensen, Paw, Peter de Nully Brown, Pär Josefsson, et al.. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal Of Haematology. 114(5). 832–839.

Grantzau, Trine, Mia Dahl Sørensen, Michael Møller, et al.. (2025). Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies. PubMed. 2(3). 100096–100096.

Dall, Elfriede, Sebastian Rasch, Simon Husby, et al.. (2025). Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study. PubMed. 2(3). 100128–100128.

Brown, Peter de Nully, Matthew J. Maurer, Arushi Khurana, et al.. (2024). The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study. Leukemia & lymphoma. 65(14). 2173–2181. 2 indexed citations

Karimi, Yasmin, Catherine Thiéblemont, Hervé Ghesquières, et al.. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7039–7039. 5 indexed citations

Vose, Julie M., Chan Y. Cheah, Michael Roost Clausen, et al.. (2024). 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4480–4480. 8 indexed citations

Nielsen, Torsten Holm, Ditte Stampe Hersby, Simon Østergaard, et al.. (2024). Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study. Blood Advances. 9(4). 893–905.

Jakobsen, Lasse, Sandra Eloranta, Karin E. Smedby, et al.. (2024). Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study. European Journal Of Haematology. 113(5). 641–650. 2 indexed citations

Sehn, Laurie H., Martine E.D. Chamuleau, Georg Lenz, et al.. (2023). PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2. Hematological Oncology. 41(S2). 849–850. 4 indexed citations

10.

Jakobsen, Lasse Hjort, Boris Modrau, Kristian Kragholm, et al.. (2023). Risk of dementia among older patients with lymphoma: A Danish nationwide matched cohort study. Journal of Geriatric Oncology. 15(1). 101672–101672. 2 indexed citations

11.

Falchi, Lorenzo, Michael Roost Clausen, Fritz Offner, et al.. (2023). HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE. Hematological Oncology. 41(S2). 207–208. 2 indexed citations

12.

Jakobsen, Lasse Hjort, Kristian Kragholm, Joachim Bæch, et al.. (2023). Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study. Clinical Epidemiology. Volume 15. 337–348. 4 indexed citations

13.

Bæch, Joachim, Marianne Tang Severinsen, Henrik Frederiksen, et al.. (2022). Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy. Blood Advances. 6(15). 4427–4435. 2 indexed citations

14.

Juul, Maja Bech, Jelena Jelicic, Henriette Engberg, et al.. (2022). Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study. Leukemia & lymphoma. 63(9). 2074–2083. 1 indexed citations

15.

Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →

16.

Clausen, Michael Roost, et al.. (2020). Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma. Cancers. 12(7). 1967–1967. 7 indexed citations

17.

Clausen, Michael Roost, Matthew J. Maurer, Sinna Pilgaard Ulrichsen, et al.. (2019). <p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. Clinical Epidemiology. Volume 11. 987–996. 7 indexed citations

18.

Clausen, Michael Roost, et al.. (2017). Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features. Blood. 130. 4148–4148. 3 indexed citations

19.

Arboe, Bente, et al.. (2015). The Danish Lymphoma Registry has a high coverage and high data quality. Haematologica. 100. 2 indexed citations

20.

El‐Galaly, Tarec Christoffer, Karen Juul Mylam, Maria Rossing, et al.. (2013). Patient-reported symptoms are still the single most important factor for detecting lymphoma relapse. Hematological Oncology. 31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact